DMRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Damora Therapeutics Inc (DMRA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of recent news or catalysts, and no strong trading signals suggest holding off on investing in this stock for now.
No significant price trend data is available. The stock closed at $26.14, down 4.26% during regular trading, with a slight post-market decline of 2.06%.
Evercore ISI initiated coverage with an Outperform rating and a $46 price target, indicating potential long-term upside.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Financial performance remains weak, with negative net income and EPS despite significant YoY improvements.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of $200.74M (up 2877.84% YoY), and an EPS of -135.6 (up 2543.27% YoY). Gross margin remains at 0%.
Evercore ISI initiated coverage with an Outperform rating and a $46 price target, suggesting long-term potential.
